.svg)
Venture Medical Announces Acquisition of Select ProgenaCare Global Assets to Expand Advanced Wound Care Portfolio
Venture Medical Announces Acquisition of Select ProgenaCare Global Assets to Expand Advanced Wound Care Portfolio
Venture Medical, LLC, a leader in wound care solutions, today announced its acquisition of certain assets of ProgenaCare Global, LLC, a biotechnology company known for its innovative, keratin-based wound healing technologies, including ProgenaMatrix®, along with intellectual property supporting an expected future product line. Howard Walthall, former CEO of ProgenaCare, has also joined Venture Medical as Senior Vice President of Product Development.
This acquisition marks a significant milestone in Venture Medical’s mission to deliver clinically proven, accessible, and ethically grounded wound care solutions to providers across the country. By integrating ProgenaCare’sproprietary keratin platform, Venture Medical strengthens its advanced therapy portfolio with regenerative technologies that support healing and help improve outcomes for patients with chronic and hard-to-heal wounds.
“Venture Medical is at the forefront of patient-centered innovation. Between their comprehensive product formulary and proprietary Venture OneView platform, they are positioned to become a nationwide leader in the wound care space,” said Bert Jones, Chairman of the Board of ProgenaCare Global. “We are excited to see our mission continue with a company that shares our values and has the infrastructure to scale our impact.”
“ProgenaCare has long stood for integrity, science, and healing — all values that align seamlessly with Venture Medical,” said John Schroeder, CEO of Venture Medical. “With Howard Walthall on board and these technologies in our portfolio, we’re positioned to elevate the standard of care and improve patient outcomes in ways that are both clinically meaningful and beneficial to the industry as a whole.”
The acquisition includes full rights to ProgenaMatrix®, the first and only keratin matrix cleared by the FDA for wound management, and contractual rights to distribute revyve™, an advanced antimicrobial hydrogel. Both products are now available through Venture Medical’s extensive distribution network.
Click here to view the official press release.
About Venture Medical, LLC:
Venture Medical is a groundbreaking healthcare services company with a decade-long history of innovation, dedication, and consistent growth in the field of wound care and healing. Over the past 15 years, Venture Medical has expanded its reach across the United States and has grown to become a leading commercial partner and software services provider for manufacturers and end users of biologics, advanced diagnostics, durable medical equipment, and capital goods.
About ProgenaCare Global, LLC:
ProgenaCare Global is a biotechnology company focused on developing keratin-based regenerative therapies. Its core technologies are designed to accelerate tissue regeneration, reduce inflammation, and promote healthy wound closure with biocompatible and biologically active materials.
Popular Posts
Categories
Avoiding wound care for free, a.k.a. surviving a “bad faith” audit.
Audits are meant to protect against fraud, but in wound care many providers are now facing aggressive “bad faith” audits driven by financial incentives and bias. This blog explores what’s behind the rise in these audits, their impact on patients and practitioners, and the steps providers can take to prepare, push back, and protect their practices.
The price patients will pay for the PFS
After a recent survey we conducted, it is clear most clinicians agreed skin substitutes are highly effective and essential, warning that the proposed rates would reduce patient access, hinder innovation, and threaten the viability of many practices. Read the blog to learn more about our findings.
The Case For Mobile Wound Care: An Essential Component Of Chronic Wound Management
Mobile wound care is a critical yet often misunderstood part of chronic wound management, providing advanced treatment to patients who can't easily access traditional care. Far from being a fringe service, it’s a large and growing field—with nearly 30,000 clinicians billing for mobile wound services in 2023 alone—and plays a key role in addressing the rising burden of chronic wounds, especially in nursing homes. As wound severity increases, staffing shortages persist, and the population ages, mobile providers are filling care gaps through high-volume, high-quality services and innovative tools like AI-assisted telehealth and near-infrared spectroscopy. To ensure better outcomes and lower healthcare costs, policymakers and payers must recognize mobile wound care as an essential, professional solution—not a peripheral one.
Venture Position on CMS and MAC Skin Substitute Proposals
Venture Medical, LCC is sharing our position on the CY2026 Medicare Physician Fee Schedule and our future recommendations.
How CMS Fudged the Math:
If we want reimbursement systems that reflect real-world care and outcomes, we need to speak up. The comment period is now open. Read the full breakdown from John Schroeder and Howard Walthall to learn more about how you can join the call for fair, evidence-based reimbursement.
